- $662.30m
- $251.53m
Olema Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Olema Oncology Q4 Net Income USD -26.772 Million
Brief: Olema Pharma Files Prospectus On Resale Of Up To 13.2 Mln Shares Of Common Stock Held By Selling Stockholders - SEC Filing
Brief: Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability With CDK4/6 Inhibitors Ribociclib And Palbociclib In Phase 1B/2 Studies
Brief: Olema Oncology Q3 Net Income USD -21.502 Million
Olema Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results For Palazestrant
Brief: Olema Oncology Kat6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
Olema Pharma up on expanded partnership with Novartis
Brief: Olema Oncology Announces Expansion Of Collaboration Agreement With Novartis
U.S. RESEARCH ROUNDUP-Arm Holdings, Expensify, New Relic
Olema Pharma hits highest in 1-1/2 years after private placement
Brief: Olema Oncology Announces Combined Financing For Up To $180 Mln
Olema Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Olema Pharmaceuticals Inc expected to post a loss of 73 cents a share - Earnings Preview
Olema Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Olema Oncology Reports First Quarter 2023 Financial Results And Provides Corporate Update